No profile data available.
Burning Rock Biotech Limited (BNR) is a healthcare company in the DNA testing equipment industry, based in Guangzhou, China, with about 667 full-time employees.
It reported revenue of 515.82 million CNY for fiscal year 2024, down 4.0% from fiscal year 2023, and net income of -346.63 million CNY. Its largest business segment, In-Hospital Channel, brought in 42% of segment revenue in fiscal year 2025; Mainland China was the largest region with 81%. Its market capitalization was $163.36 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Burning Rock Biotech reported 515.82 million CNY in revenue for fiscal year 2024, down 4.0% from 537.44 million CNY in fiscal year 2023.
In-Hospital Channel, with 224.04 million CNY or 42% of segment revenue in fiscal year 2025. Next: Central Laboratory Channel (30%) and Pharma Research and Development Channel (29%).
Mainland China: 81% of revenue by region in fiscal year 2025, followed by Overseas (19%).
$163.36 million as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include CareDx, Inc (CDNA), Castle Biosciences, Inc. (CSTL), Myriad Genetics, Inc. (MYGN), Cardiff Oncology, Inc. (CRDF).